Thuja Capital

Synerkine Pharma is engaged in the development of novel fusion proteins aimed at treating inflammatory, neuropathic, and osteoarthritic pain. The company's innovative protein targets key regulatory mechanisms associated with various forms of chronic pain, offering unique properties that help normalize pain and inhibit inflammation. This approach enables patients to access effective pharmaceutical solutions designed to reduce pain across multiple pre-clinical models.

ATRO Medical B.V., based in Nijmegen, the Netherlands, specializes in the development of an anatomically shaped polymer-based meniscus implant known as the Trammpolin. This innovative implant is designed to restore the protective function of the meniscus by acting as a spacer in the joint. ATRO Medical emerged as a spin-out from DSM and Radboudumc, leveraging expertise gained from a collaborative initiative that began in 2010, which included universities, private companies, and support from the Dutch government. The company combines clinical, biomechanical, and polymer knowledge to advance the Trammpolin design and its prototype development.

Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies for individuals with chronic neurological diseases. The company operates in the burgeoning field of bioelectronics, merging principles of biology and electronics to create innovative therapeutic solutions. The name "Salvia," derived from the Latin word for "to stay healthy," reflects the company's commitment to enhancing health and well-being. Salvia aims to deliver accessible bioelectronic treatments that address severe neurological disorders. The team comprises experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, ensuring a strong foundation for the development of their cutting-edge technologies.

NutriLeads is an innovative startup that develops nutritional ingredients with demonstrated health effects. NutriLeads aims to catalyze nutritional health innovation in the food industry by partnering with relevant companies to identify promising lead ingredients, develop sustainable and commercially viable production processes, and initiate scientific & clinical programs to substantiate the health effects of these ingredients. Together we will bring the benefits of the proprietary ingredients to patients and consumers.

Synerkine Pharma is engaged in the development of novel fusion proteins aimed at treating inflammatory, neuropathic, and osteoarthritic pain. The company's innovative protein targets key regulatory mechanisms associated with various forms of chronic pain, offering unique properties that help normalize pain and inhibit inflammation. This approach enables patients to access effective pharmaceutical solutions designed to reduce pain across multiple pre-clinical models.

Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies for individuals with chronic neurological diseases. The company operates in the burgeoning field of bioelectronics, merging principles of biology and electronics to create innovative therapeutic solutions. The name "Salvia," derived from the Latin word for "to stay healthy," reflects the company's commitment to enhancing health and well-being. Salvia aims to deliver accessible bioelectronic treatments that address severe neurological disorders. The team comprises experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, ensuring a strong foundation for the development of their cutting-edge technologies.

Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies for individuals with chronic neurological diseases. The company operates in the burgeoning field of bioelectronics, merging principles of biology and electronics to create innovative therapeutic solutions. The name "Salvia," derived from the Latin word for "to stay healthy," reflects the company's commitment to enhancing health and well-being. Salvia aims to deliver accessible bioelectronic treatments that address severe neurological disorders. The team comprises experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, ensuring a strong foundation for the development of their cutting-edge technologies.

Mellon Medical B.V. is a medical device company based in Nijmegen, the Netherlands, that specializes in developing and marketing innovative suturing tools for surgeons. Founded in 2013, the company focuses on enhancing surgical procedures by providing instruments that enable single-handed stitching, thereby improving the efficiency and effectiveness of suturing tubular and layered structures. Mellon Medical aims to support medical specialists in achieving better patient outcomes through its advanced suturing solutions.

ATRO Medical B.V., based in Nijmegen, the Netherlands, specializes in the development of an anatomically shaped polymer-based meniscus implant known as the Trammpolin. This innovative implant is designed to restore the protective function of the meniscus by acting as a spacer in the joint. ATRO Medical emerged as a spin-out from DSM and Radboudumc, leveraging expertise gained from a collaborative initiative that began in 2010, which included universities, private companies, and support from the Dutch government. The company combines clinical, biomechanical, and polymer knowledge to advance the Trammpolin design and its prototype development.

NutriLeads is an innovative startup that develops nutritional ingredients with demonstrated health effects. NutriLeads aims to catalyze nutritional health innovation in the food industry by partnering with relevant companies to identify promising lead ingredients, develop sustainable and commercially viable production processes, and initiate scientific & clinical programs to substantiate the health effects of these ingredients. Together we will bring the benefits of the proprietary ingredients to patients and consumers.

MILabs B.V. manufactures preclinical nuclear imaging systems. Its preclinical imaging systems include X-ray and optical imaging systems. The company also provides clinical imaging systems, such as G-SPECT, an advanced full-ring SPECT system for imaging various isotopes. In addition, it offers materials imaging solutions for nanomedicine, environmental, and agricultural applications, as well as food, chemistry, and process control industries. The company’s instruments are used for imaging applications in various fields, including pharmacology, oncology, cardiology, bone research, diabetes, and neuroscience. MILabs B.V. was founded in 2006 and is based in Utrecht, the Netherlands.

NightBalance B.V. develops and markets an obstructive sleep apnea (OSA) device for the treatment of positional obstructive sleep apnea to customers in Europe. It develops Sleep Position Trainer (SPT), which measures the sleep behavior of the patient continuously; gives a gentle vibration once the patient turns into the supine position; and reminds the patient to change their sleeping position without disrupting their natural sleeping architecture. The company was founded in 2009 and is based in The Hague, the Netherlands. As of May 8, 2018, NightBalance B.V. operates as a subsidiary of Koninklijke Philips N.V.

NutriLeads is an innovative startup that develops nutritional ingredients with demonstrated health effects. NutriLeads aims to catalyze nutritional health innovation in the food industry by partnering with relevant companies to identify promising lead ingredients, develop sustainable and commercially viable production processes, and initiate scientific & clinical programs to substantiate the health effects of these ingredients. Together we will bring the benefits of the proprietary ingredients to patients and consumers.

FABPulous B.V. develops and markets diagnostic solutions for primary care and emergency medicine sectors. The company offers H-FABP True Rapid Test, a blood filtration device that detects a small protein found in capillary blood after a heart attack; and a test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP) to aid in the first-line diagnosis of acute myocardial infarction. It provides products through a network of distributors. The company was founded in 2008 and is based in Maastricht, the Netherlands.

Hemics BV, a medical device company, provides solutions for rheumatoid arthritis (RA). It offers HandScan, a non-invasive imaging system for monitoring the inflammatory status of RA patients. The company's HandScan is a non-invasive optical imaging device that supports the rheumatologist in objective assessment of inflammatory status in RA. Hemics BV was formerly known as Akeso Medical Imaging BV and changed its name to Hemics BV in April 2013. The company was founded in 2011 and is based in Eindhoven, the Netherlands.

Cristal Therapeutics BV operates as a clinical stage pharmaceutical company. It develops nanomedicines based on its proprietary CriPec and CriPec ATN platform to treat diseases which include cancer. The company develops technology to transform drugs into nanoparticles. It also provides programs to develop nanomedicines for various therapeutic areas. The company was founded in 2011 and is based in Maastricht, the Netherlands.

EnCare Biotech B.V., established in 2014 and located in Utrecht, the Netherlands, is a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies aimed at preventing heart failure following acute myocardial infarction. The company's primary focus is on the Fibronectin-EDA monoclonal antibody, which offers a novel approach to preventing chronic heart failure. EnCare's strategy combines a strong scientific foundation with expertise in manufacturing, regulatory affairs, and clinical development, supported by a network of industry experts. This collaborative approach enhances its ability to navigate the complexities of biopharmaceutical development. The management team is experienced in business development and has established connections in areas such as intellectual property and corporate law, which bolster EnCare's strategic initiatives. Operating with a lean model, EnCare manages key functions in-house while outsourcing operational activities to high-quality external providers, ensuring efficiency and adherence to industry standards.

NightBalance B.V. develops and markets an obstructive sleep apnea (OSA) device for the treatment of positional obstructive sleep apnea to customers in Europe. It develops Sleep Position Trainer (SPT), which measures the sleep behavior of the patient continuously; gives a gentle vibration once the patient turns into the supine position; and reminds the patient to change their sleeping position without disrupting their natural sleeping architecture. The company was founded in 2009 and is based in The Hague, the Netherlands. As of May 8, 2018, NightBalance B.V. operates as a subsidiary of Koninklijke Philips N.V.

Mellon Medical B.V. is a medical device company based in Nijmegen, the Netherlands, that specializes in developing and marketing innovative suturing tools for surgeons. Founded in 2013, the company focuses on enhancing surgical procedures by providing instruments that enable single-handed stitching, thereby improving the efficiency and effectiveness of suturing tubular and layered structures. Mellon Medical aims to support medical specialists in achieving better patient outcomes through its advanced suturing solutions.

Hemics BV, a medical device company, provides solutions for rheumatoid arthritis (RA). It offers HandScan, a non-invasive imaging system for monitoring the inflammatory status of RA patients. The company's HandScan is a non-invasive optical imaging device that supports the rheumatologist in objective assessment of inflammatory status in RA. Hemics BV was formerly known as Akeso Medical Imaging BV and changed its name to Hemics BV in April 2013. The company was founded in 2011 and is based in Eindhoven, the Netherlands.

NightBalance B.V. develops and markets an obstructive sleep apnea (OSA) device for the treatment of positional obstructive sleep apnea to customers in Europe. It develops Sleep Position Trainer (SPT), which measures the sleep behavior of the patient continuously; gives a gentle vibration once the patient turns into the supine position; and reminds the patient to change their sleeping position without disrupting their natural sleeping architecture. The company was founded in 2009 and is based in The Hague, the Netherlands. As of May 8, 2018, NightBalance B.V. operates as a subsidiary of Koninklijke Philips N.V.

FABPulous B.V. develops and markets diagnostic solutions for primary care and emergency medicine sectors. The company offers H-FABP True Rapid Test, a blood filtration device that detects a small protein found in capillary blood after a heart attack; and a test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP) to aid in the first-line diagnosis of acute myocardial infarction. It provides products through a network of distributors. The company was founded in 2008 and is based in Maastricht, the Netherlands.

CAVΛDIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. They develop prognostic tests to identify patients at risk of cardiovascular and disease. The company identified several novel biomarkers predictive for cardiovascular events. It is their goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.

DCPrime is a clinical-stage cancer immunotherapy company, which develops therapeutic vaccines based on its proprietary DCOne platform. DCOne‐based vaccines share all immune‐stimulatory properties with patient-derived dendritic cell‐based vaccines, and have the simple logistics of off‐the‐shelf products. DCOne cells express a range of known tumor antigens, which are targeted in several cancer types.

Bioceros B.V. operates as a biopharmaceutical research and development contract organization. The company focuses on providing a range of technical and scientific expertise ranging from discovery research to pre-clinical development. Its services include assay development and quantification, pre-clinical development, molecular biology, cell biology and immunology, protein expression in various systems, upscaling/fermentation, protein purification, and consulting services. The company offers its services to other biotech companies, academic institutions, and pharmaceutical companies. Bioceros B.V. was founded in 2003 and is based in Utrecht, the Netherlands.

CAVΛDIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. They develop prognostic tests to identify patients at risk of cardiovascular and disease. The company identified several novel biomarkers predictive for cardiovascular events. It is their goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.

Avantium is a technology company based in Amsterdam, specializing in advanced high-throughput research and development for the energy, chemicals, and pharmaceutical sectors. It employs proprietary technology that accelerates and reduces the costs associated with developing new products and processes. Avantium's innovative approach to experiment design and data analysis enhances its success rate in delivering effective solutions. The company has successfully collaborated with over 70 global clients, showcasing the commercial viability of its services. Avantium focuses on two primary areas: developing biofuels and bio-based chemicals, as well as new crystal forms of patented drugs. Its business model includes a strong emphasis on expanding its patent portfolio and establishing partnerships that add value. Additionally, Avantium operates through segments such as R&D Solutions, Renewable Chemistries, and Renewable Polymers, with the R&D Solutions segment generating the majority of its revenue. The company is supported by a team of experts in various fields, including catalysis, organic chemistry, and software development, who work closely with partner organizations to drive innovation in sustainable chemistry.